Meletios Dimopoulos, MD, National and Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses the use of selinexor in the treatment of multiple myeloma, highlighting its initial challenges with gastrointestinal toxicity. However, recent use of selinexor at lower doses in combination with bortezomib and dexamethasone (SVd) has shown to be both effective and relatively well-tolerated, and could be used for patients with limited access to other treatments. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
